-
Product Insights
NewFibromyalgia (Fibromyalgia Syndrome) – Drugs In Development, 2024
Empower your strategies with our Fibromyalgia (Fibromyalgia Syndrome) – Drugs In Development, 2024 report and make more profitable business decisions. Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory, and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis, or lupus. Treatment includes pain relievers, antidepressants, and anti-seizure drugs. The Fibromyalgia (Fibromyalgia Syndrome) drugs in development market research report provide comprehensive information...
-
Sector Analysis
Chronic Low Back Pain (CLBP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
CLBP Marketed and Pipeline Drugs Report Overview Chronic low back pain (CLBP) is defined as pain that continues for 12 weeks or longer, even after an initial injury or underlying cause of acute low back pain (BP) has been treated. It represents the second-leading cause of disability worldwide and is a major health and economic problem. CLBP is a complex disease with high heterogeneity and is increasingly dubbed a mixed pain syndrome with neuropathic and injurious components. CLBP develops in...